Please assess the completion status of the following clinical trial:

Trial Title: Ilaris (Canakinumab) in the Schnitzler Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active Schnitzler syndrome after withdrawal of anakinra or tapering of corticosteroids.~* Male and female patients at least 18 years of age at the time of screening visit.~* Signed patient informed consent~* Negative QuantiFERON test or negative Purified Protein Derivative (PPD) test (\<5 mm induration) at screening or within 1 month prior to the screening visit, according to Belgium guidelines. Patients with a positive PPD test (=5 mm induration) at screeninig may be enrolled only if they have a negative chest x-ray or negative QuantiFERON test (QFT-TB G In-Tube).~* Adequate contraception in females of childbearing potential.~Exclusion Criteria:~* Pregnant or nursing (lactating) women~* History of being immunocompromised, including a positive HIV at screening (ELISA and Western blot)~* Serologic evidence of active hepatitis B or C infection~* Live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose.~* History of significant medical conditions, which in the investigator's opinion would exclude the patient from participating in this trial.~* History of recurrent and/or evidence of active bacterial, fungal or viral infection(s).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Canakinumab (Type: EXPERIMENTAL): * Canakinumab 150 mg (or 2 mg/kg for patients weighing \<40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~* At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing \<40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing \<40 kg) every 8 weeks beginning at Week 8.~* Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~* If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).